Plain-English translation of NCT05768139 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first times this treatment has been tested in people.
This is a first-in-human trial testing (tersolisib), a new cancer medication designed to target tumors with a specific genetic mutation called PI3Kα. The study is testing whether this medication works well and is safe when given by itself or combined with other cancer treatments, particularly for breast cancer and other solid tumors. Researchers want to find the right dose and understand how the medication works in your body.
Many cancers have a PI3Kα genetic mutation that helps them grow. This medication is designed specifically to block this mutation, potentially stopping cancer cells from multiplying while sparing healthy cells. This is a new approach that hasn't been tested in humans before, so researchers need to learn if it's effective and safe.
You likely qualify if…
You likely don't qualify if…
You will have a screening period of about four weeks where doctors will take a tumor biopsy and run blood tests to confirm you're eligible. If enrolled, you'll receive either alone or combined with other cancer medications depending on which group you're in. You'll have regular clinic visits to check how you're tolerating the medication, with blood work and scans to monitor whether the cancer is responding. The study involves multiple treatment groups testing different combinations, so your specific schedule will depend on which arm of the study you join.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
United States